Alx Oncology Holdings (ALXO) Cash from Operations Growth (1y) (2020 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 60.84% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 85.14% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.72% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 74.39% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 3.23% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 158.60% |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | 24.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.39% |
| Dec 31, 2025 | 40.77% |
| Sep 30, 2025 | 32.64% |
| Jun 30, 2025 | 11.89% |
| Mar 31, 2025 | 34.97% |
| Dec 31, 2024 | 19.23% |
| Sep 30, 2024 | 18.56% |
| Jun 30, 2024 | 16.22% |
| Mar 31, 2024 | -36.34% |
| Dec 31, 2023 | -91.98% |
| Sep 30, 2023 | -0.89% |
| Jun 30, 2023 | -86.56% |
| Mar 31, 2023 | -34.55% |
| Dec 31, 2022 | -18.18% |
| Sep 30, 2022 | -24.25% |
| Jun 30, 2022 | 17.57% |
| Mar 31, 2022 | -302.61% |
| Dec 31, 2021 | -28.45% |
| Sep 30, 2021 | -160.33% |
| Jun 30, 2021 | -234.61% |
| Mar 31, 2021 | 42.71% |
| Dec 31, 2020 | -373.73% |
| Sep 30, 2020 | -199.69% |